Results from the TRAPID-AMI clinical study have been published online by the Annals of Emergency Medicine, confirming a novel approach for a more rapid diagnosis of heart attack in patients with acute ...

Please provide your email address to receive an email when new articles are posted on . Roche Diagnostics Corp. announced that the FDA has cleared its next-generation troponin T assay for use in ...

US physicians who’ve been waiting to get their hands on high-sensitivity troponin tests don’t have to wait any longer. Last week, the US Food and Drug Administration (FDA) gave 510(k) clearance to the ...

A single high-sensitivity cardiac troponin T (hs-cTnT) test with findings below the level of detection, teamed with a nonischemic electrocardiogram (ECG), can identify patients with chest pain in the ...

Basel, Switzerland - Roche Diagnostics received clearance this week from the FDA for the Elecsys ® Troponin T STAT test as an aid in the differential diagnosis of acute coronary syndrome, for risk ...

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies. The test helps clinicians quickly identify heart attack and ...

The current lower limit for detection of plasma troponin T in most commercially available tests is approximately 0.01 μg/l, and levels higher than this value are associated with increased mortality.

Roche announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack. With this clearance, Roche is ...

High-sensitivity cardiac troponin assays may eventually play a part in an overall strategy for evaluating patients who present with stable chest pain symptoms and possible coronary disease, an ...

Cardiac troponin T is a protein biomarker detectable with a blood test, and it is the preferred biomarker for determining cardiovascular risk. In a new study published in JAMA Cardiology, researchers ...